RhBMP2 was used in thirty-six consecutive patients requiring interbody fusion with fifty-five levels (thirteen patients twenty levels ALIF, twelve patients seventeen levels TLIF, eleven patients eighteen levels ACDF) using anterior cervical locking plates and lumbar posterior pedicle screw constructs. All patients showed radiographic fusion at six months. Early lucency, subsidence, and increased pain occurred between six weeks and three months in 70% of ALIFS, 53% of TLIFS and 33% of ACDF’s. The average subsidence was 27% in ALIFS, 24% in TLIFS, and 53% in ACDF. Pain improved by the sixth month. We recommend alternative structural support when using RhBMP2.

To determine effectiveness of RhBMP2 in interbody fusion with machined allograft spacers (MTF Synthes Spine USA femoral ring, TLIF and fibular ring cervical spacers)

A prospective study of thirty-six consecutive patients requiring interbody fusion with fifty-five levels (thirteen patients twenty levels ALIF, twelve patients seventeen levels TLIF, eleven patients eighteen levels ACDF). Machined allograft spacers and RhBmp2 were supplemented with anterior locking plates in the cervical spine while the lumbar segments were supplemented posterior pedicle screws constructs. Patients were followed at two weeks, six weeks, three months, six months, one year. Patients were examined, had xrays, completed Oswestry scores, pain diagrams, and VAS for pain preoperatively and at every follow up appointment.

All the patients showed radiographic evidence of fusion at six months after surgery. Early lucency and subsidence of allografts was observed in 70% of ALIFS, 53% of TLIFS and 33% of ACDF’s. The average subsidence was 27% (range13–42%) in ALIFS, 24% in TLIFS (range 13–40%), and 53% in ACDF. Subsidence and reporting of increased pain occurred between the six- week and three month follow up after which patients improved.

Although high rates of early fusion can be accomplished with allograft spacers and rhBMP2 significant subsidence occurs in greater than 50% of lumbar cases and 30% of cervical cases due to early turnover and loss of structural support of the allograft. We recommend alternative structural support when using RhBMP2.